1. T Zhang#, R Qu#, SP Chan#, MZ Lai, LJ Tong, F Feng, HY Chen, TT Song, PR Song, G Bai, YQ Liu, YN Wang, Y Li, Y Su, YY Shen, YM Sun, Y Chen, MY Geng, K Ding*, J Ding*, H Xie*. Discovery of a novel third- generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. Mol Cancer. 2020 May 13;19(1):90.
2. MZ Lai#, PR Song#, D Dou#, YY Diao, LJ Tong, T Zhang, H Xie*, HL Li*, J Ding*. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl) phenyl)amino)-4-methyl-2- oxo-2Hpyrimido[4,5-d][1,3]oxazin-1(4H)-ly)phenyl)acrylamide as potent Bruton’s tyrosine kinase inhibitors. Acta Pharm Sin. 2020 Mar;41(3):415-422.
3. Z Chen#, LJ Tong, BY Tang, HY Liu, X Wang, T Zhang, XW Cao, Y Chen, HL Li, XH Qian, YF Xu*, H Xie*, J Ding*. C11, a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor, suppresses breast cancer metastasis and angiogenesis. Acta Pharma Sin. 2019 Jun;40(6):823-832.
4. H Xie#, MH Lee#, F Zhu#, K Reddy#, C Peng, Y Li, DY Lim, DJ Kim, X Li, S Kang, HT Li, WY Ma, RA Lubet, J Ding, AM Bode, ZG Dong*. Identification of an Aurora kinase inhibitor specific for the Aurora B isoform. Cancer Res. 2013 Jan 15;73(2):716-724.
5. H Xie#, MH Lee#, F Zhu#, Reddy K, ZN Huang, DJ Kim, Y Li, C Peng, DY Lim, S Kang, SK Jung, X Li, HT Li, WY Ma, RA Lubet, J Ding, AM Bode, ZG Dong*. Discovery of the novel mTOR inhibitor and its antitumor activities in vitro and in vivo. Mol Cancer Thera. 2013 Jun;12(6):950-958.